These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 2567971

  • 21. Biphasic effect of locally applied apomorphine and 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine on the release of striatal dopamine investigated by means of brain dialysis.
    Kurata K, Shibata R.
    Neurosci Lett; 1990 Sep 18; 117(3):264-8. PubMed ID: 1982738
    [Abstract] [Full Text] [Related]

  • 22. D2 dopamine receptor-mediated mechanisms in the medial preoptic-anterior hypothalamus regulate effective defense behavior in the cat.
    Sweidan S, Edinger H, Siegel A.
    Brain Res; 1991 May 17; 549(1):127-37. PubMed ID: 1680019
    [Abstract] [Full Text] [Related]

  • 23. N-methyl-D-aspartate receptor blockade differentially modifies regional cerebral metabolic responses to D1 and D2 dopamine agonists in rats with a unilateral 6-hydroxydopamine lesion.
    Engber TM, Anderson JJ, Boldry RC, Kuo S, Chase TN.
    Neuroscience; 1993 Jun 17; 54(4):1051-61. PubMed ID: 8101981
    [Abstract] [Full Text] [Related]

  • 24. Dopamine receptor subtypes and formalin test analgesia.
    Morgan MJ, Franklin KB.
    Pharmacol Biochem Behav; 1991 Oct 17; 40(2):317-22. PubMed ID: 1687167
    [Abstract] [Full Text] [Related]

  • 25. Evidence for post-synaptic changes mediating increased behavioural sensitivity to dopamine receptor agonists in hypothyroid rats.
    Crocker AD, Cameron DL.
    Prog Neuropsychopharmacol Biol Psychiatry; 1988 Oct 17; 12(5):607-15. PubMed ID: 3065827
    [Abstract] [Full Text] [Related]

  • 26. Haloperidol and clozapine: differential effects on the sensitivity of caudate-putamen neurons to dopamine agonists and cholecystokinin following one month continuous treatment.
    Hu XT, Wang RY.
    Brain Res; 1989 May 08; 486(2):325-33. PubMed ID: 2786442
    [Abstract] [Full Text] [Related]

  • 27. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK, Manzino L, Heikkila RE.
    J Pharmacol Exp Ther; 1988 Oct 08; 247(1):180-5. PubMed ID: 2971797
    [Abstract] [Full Text] [Related]

  • 28. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM, Marin C, Susel Z, Chase TN.
    Eur J Pharmacol; 1993 Jun 04; 236(3):385-93. PubMed ID: 8102970
    [Abstract] [Full Text] [Related]

  • 29. Role of dopamine D-1 and D-2 receptors in the regulation of neurotensin systems of the neostriatum and the nucleus accumbens.
    Merchant KM, Gibb JW, Hanson GR.
    Eur J Pharmacol; 1989 Feb 07; 160(3):409-12. PubMed ID: 2565819
    [Abstract] [Full Text] [Related]

  • 30. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems.
    Singh NA, Bush LG, Gibb JW, Hanson GR.
    Brain Res; 1992 Feb 07; 571(2):260-4. PubMed ID: 1351780
    [Abstract] [Full Text] [Related]

  • 31. Acute reduction of dopamine levels alters responses of basal ganglia neurons to selective D-1 and D-2 dopamine receptor stimulation.
    Carlson JH, Bergstrom DA, Demo SD, Walters JR.
    Eur J Pharmacol; 1988 Aug 02; 152(3):289-300. PubMed ID: 2906003
    [Abstract] [Full Text] [Related]

  • 32. Differential effects of pallidal lesions on the behavioural responses to SKF 38393, LY 171555 and apomorphine in the rat.
    Fletcher GH, Starr MS.
    Neuroscience; 1989 Aug 02; 28(1):171-80. PubMed ID: 2569694
    [Abstract] [Full Text] [Related]

  • 33. Specific D1 and D2 dopamine agonists have synergistic effects in the 6-hydroxydopamine circling model in the rat.
    Rouillard C, Bédard PJ.
    Neuropharmacology; 1988 Dec 02; 27(12):1257-64. PubMed ID: 2907616
    [Abstract] [Full Text] [Related]

  • 34. Locomotor bias produced by intra-accumbens injection of dopamine agonists and antagonists.
    Messier C, Mrabet O, Destrade C.
    Pharmacol Biochem Behav; 1992 Jan 02; 41(1):177-82. PubMed ID: 1347172
    [Abstract] [Full Text] [Related]

  • 35. Postnatal lead exposure induces supersensitivity to the stimulus properties of a D2-D3 agonist.
    Cory-Slechta DA, Pokora MJ, Widzowski DV.
    Brain Res; 1992 Dec 11; 598(1-2):162-72. PubMed ID: 1362517
    [Abstract] [Full Text] [Related]

  • 36. Yawning produced by dopamine agonists in rhesus monkeys.
    Code RA, Tang AH.
    Eur J Pharmacol; 1991 Aug 29; 201(2-3):235-8. PubMed ID: 1686760
    [Abstract] [Full Text] [Related]

  • 37. Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study.
    Sesack SR, Bunney BS.
    J Pharmacol Exp Ther; 1989 Mar 29; 248(3):1323-33. PubMed ID: 2564893
    [Abstract] [Full Text] [Related]

  • 38. Effects of D1 and D2 antagonists on the transient increase of dopamine release by dopamine agonists by means of brain dialysis.
    Kurata K, Shibata R.
    Neurosci Lett; 1991 Nov 25; 133(1):77-80. PubMed ID: 1686482
    [Abstract] [Full Text] [Related]

  • 39. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Nov 25; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 40. Production of climbing behaviour in mice requires both D1 and D2 receptor activation.
    Moore NA, Axton MS.
    Psychopharmacology (Berl); 1988 Nov 25; 94(2):263-6. PubMed ID: 2895485
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.